Who is Dr. Sandra J. Horning and what is her role on the board?

Dr. Sandra J. Horning has been elected to the Board of Directors of Gilead Sciences, Inc. She has also been appointed as a member of the Nominating and Corporate Governance Committee and the Scientific Committee. Her appointment is effective immediately from January 28, 2020.

How will Dr. Horning be compensated for her role as a director?

Dr. Horning will participate in Gilead's standard non-employee director compensation programs. This includes a pro-rated equity grant consisting of options to purchase 3,837 shares of common stock and restricted stock units for an additional 632 shares, along with a pro-rated cash retainer of $48,836.

Who has been appointed as the Principal Accounting Officer, and what is their background?

Diane E. Wilfong, Senior Vice President, Corporate Controller and Chief Accounting Officer, has been designated as the Principal Accounting Officer for Gilead's SEC filings. Ms. Wilfong joined Gilead in February 2016 and has prior experience in similar roles at Computer Sciences Corporation, Caesars Entertainment Corporation, and Eastman Kodak Company.

Are there any conflicts of interest or related party transactions associated with these appointments?

The filing explicitly states that there are no arrangements or understandings pursuant to which Dr. Horning or Ms. Wilfong were selected, and no related party transactions reportable under Item 404(a) of Regulation S-K. Ms. Wilfong also has no family relationship with any director or executive officer.

GILD 8-K: Leadership Changes

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K report on January 31, 2020, primarily announcing two key personnel changes. The Board of Directors appointed Dr. Sandra J. Horning as a new director, effective immediately, and also a member of the Nominating and Corporate Governance Committee and the Scientific Committee. Dr. Horning's appointment is standard, with no reportable related party transactions. She will participate in the company's non-employee director compensation program, receiving pro-rated equity grants (stock options and RSUs) and a cash retainer. Additionally, the company designated Diane E. Wilfong as the principal accounting officer for SEC filings, effective January 29, 2020. Ms. Wilfong, who joined Gilead in 2016 as SVP, Corporate Controller and Chief Accounting Officer, has extensive experience in accounting and financial roles at major corporations. Her designation is also routine, with no disclosed arrangements or related party transactions. These appointments bring new expertise to the board and ensure clear financial reporting oversight.

Key Highlights

1Dr. Sandra J. Horning appointed to the Board of Directors.
2Dr. Horning also appointed to the Nominating and Corporate Governance Committee and the Scientific Committee.
3Dr. Horning to receive standard non-employee director compensation, including equity grants and cash retainer.
4Diane E. Wilfong designated as the Principal Accounting Officer for SEC filings.
5Ms. Wilfong has significant experience as a Corporate Controller and Chief Accounting Officer.
6No reportable related party transactions or special arrangements disclosed for either appointment.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Jan 31, 2020)

Summary

Key Highlights

Frequently Asked Questions